GLP-1 Agonist Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

What’s the Latest Research in Weight Loss Medications Telling Us?

Beyond the Hype: Innovating Obesity Treatments for Real-World Impact

Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate

Obesity-Focused Metsera Launches IPO Amid Much Anticipation

February 5, 2025

New Zepbound TV Commercial Inspires ‘Change’

January 29, 2025

GLP-1 Agonist Development: Endpoint Strategies to Help Differentiate Your Drug

February 25, 2025

Eli Lilly’s Tirzepatide Shows Promise for Keeping Prediabetic Patients Diabetes-Free

November 21, 2024

FDA Warns of Dosing Errors with Compounded Semaglutide Injectables

Sarcopenia: Changes and Challenges in Body Composition with GLP-1 Receptor Agonist-based Weight Loss Therapies

September 06, 2024

Efruxifermin Combined with GLP-1RA Shows Clinical Efficacy in MASH, Study Reveals

The Future of GLP-1 Receptor Agonists: A Precision Medicine Approach

The Next Frontier in Metabolic Management: A Personal Insight into GLP-1 Receptor Agonists

A Pathway to Better Health: How Supply Chains Deliver on the Promise of GLP-1 Drugs

Solving unmet needs in GLP1 cardiometabolic clinical trials: novel approaches to digital data capture and patient retention

Weight Loss Blockbuster Wegovy Wins Expanded Approval for Heart Benefits

Novo Nordisk Fends Calls About Ozempic from “Scared” Junk Food Makers

February 9, 2024

Next Page »